Stephen J Ruoss, MD
Critical Care (Intensivists) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ruoss’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G57078 · Current
Licensed to practise in California · since 1986 · expires 2028-01-31 · University of Washington School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$51,978
Medicare paid this office $51,978 for 166 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 58 | $33,982 | $185 |
| Return visit (30+ min) | 58 | $6,994 | $81 |
| Return visit (30+ min) | 17 | $2,445 | $111 |
| Short return visit (20+ min) | 27 | $1,842 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,271 | $71 |
Who their Medicare patients are
166 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 10% · Women 70% · Also on Medicaid 24% · Health risk score 1.94. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 2.58.
Conditions among them: High blood pressure 68% · COPD 58% · Coronary heart disease 41% · Chronic kidney disease 41% · Heart failure 40% · Atrial fibrillation 40% · Diabetes 30% · Depression 26% · Stroke 22% · Cancer 18% · Dementia 14%.
The office billed $444,187, Medicare allowed $66,426 and paid $51,978; for 405 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 166 | 405 | 73 | 1.94 | $444,187 | $51,978 |
| 2023 | 215 | 647 | 72 | 2.00 | $928,470 | $95,710 |
| 2022 | 263 | 718 | 72 | 1.92 | $818,393 | $96,085 |
| 2021 | 243 | 630 | 72 | 1.89 | $866,161 | $95,243 |
| 2020 | 294 | 813 | 71 | 1.99 | $985,731 | $126,521 |
| 2019 | 311 | 815 | 71 | 2.07 | $912,295 | $117,178 |
| 2018 | 265 | 684 | 72 | 2.10 | $707,926 | $90,848 |
| 2017 | 305 | 798 | 73 | 1.94 | $820,855 | $111,490 |
| 2016 | 272 | 740 | 71 | 1.92 | $743,458 | $101,659 |
| 2015 | 252 | 594 | 71 | 2.12 | $508,652 | $76,535 |
| 2014 | 331 | 834 | 71 | 1.94 | $691,172 | $113,355 |
| 2013 | 335 | 931 | 71 | 1.95 | $817,521 | $133,023 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Critical care, first 30-74 minutes | 100 | $75,767 | $192 |
| Return visit (30+ min) | 70 | $9,086 | $84 |
| Short return visit (20+ min) | 48 | $3,391 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,897 | $73 |
2022: 5 services
| Critical care, first 30-74 minutes | 98 | $67,877 | $194 |
| Return visit (30+ min) | 102 | $13,434 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $4,092 | $65 |
| Short return visit (20+ min) | 43 | $2,688 | $48 |
| New patient visit (45+ min) | 14 | $1,362 | $97 |
2021: 5 services
| Critical care, first 30-74 minutes | 112 | $74,700 | $198 |
| Return visit (30+ min) | 69 | $8,997 | $87 |
| Short return visit (20+ min) | 58 | $4,089 | $58 |
| New patient visit (45+ min) | 13 | $1,769 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $1,718 | $95 |
2020: 6 services
| Critical care, first 30-74 minutes | 156 | $103,359 | $202 |
| Return visit (30+ min) | 71 | $6,681 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $3,995 | $97 |
| Short return visit (20+ min) | 44 | $2,449 | $42 |
| Diagnostic exam of lung airway using an endoscope | 12 | $2,084 | $123 |
| New patient visit (45+ min) | 16 | $1,809 | $113 |
2019: 5 services
| Critical care, first 30-74 minutes | 154 | $93,618 | $198 |
| Return visit (30+ min) | 47 | $5,311 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $5,188 | $94 |
| Short return visit (20+ min) | 80 | $3,612 | $36 |
| New patient visit (45+ min) | 11 | $1,283 | $117 |
2018: 5 services
| Critical care, first 30-74 minutes | 121 | $74,216 | $189 |
| Short return visit (20+ min) | 94 | $5,544 | $39 |
| Return visit (30+ min) | 33 | $2,593 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $2,452 | $91 |
| New patient visit (30+ min) | 17 | $989 | $58 |
2017: 4 services
| Critical care, first 30-74 minutes | 165 | $92,338 | $196 |
| Short return visit (20+ min) | 101 | $7,181 | $39 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $6,170 | $92 |
| New patient visit (30+ min) | 14 | $696 | $50 |
2016: 4 services
| Critical care, first 30-74 minutes | 123 | $80,526 | $194 |
| Short return visit (20+ min) | 102 | $6,602 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $4,815 | $93 |
| New patient visit (30+ min) | 29 | $1,833 | $63 |
2015: 5 services
| Critical care, first 30-74 minutes | 104 | $59,572 | $195 |
| Short return visit (20+ min) | 90 | $6,659 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $4,527 | $92 |
| New patient visit (30+ min) | 25 | $1,548 | $62 |
| Test to measure lung function at high altitude | 11 | $143 | $13 |
2014: 6 services
| Critical care, first 30-74 minutes | 159 | $91,354 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $8,503 | $92 |
| Short return visit (20+ min) | 92 | $6,465 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $1,537 | $64 |
| New patient visit (15+ min) | 14 | $560 | $40 |
| Test to measure lung function at high altitude | 20 | $259 | $13 |
2013: 5 services
| Critical care, first 30-74 minutes | 175 | $111,574 | $191 |
| Short return visit (20+ min) | 108 | $7,091 | $40 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $6,351 | $89 |
| New patient visit (15+ min) | 28 | $1,080 | $39 |
| Test to measure lung function at high altitude | 13 | $169 | $13 |
Medicaid work
$16,299 in 2024
Medicaid paid $16,299 for 116 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 116 | $16,299 |
| 2024 | 116 | 1 | 15 | $16,299 |
| 2023 | 99 | 1 | 27 | $14,769 |
| 2022 | 152 | 1 | 18 | $11,048 |
| 2021 | 217 | 1 | 19 | $14,822 |
| 2020 | 268 | 1 | 17 | $34,464 |
| 2019 | 25 | 1 | 12 | $926 |
| 2018 | 54 | 1 | 12 | $9,819 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 99 | $14,769 |
2022
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 152 | $11,048 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 217 | $14,822 |
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 268 | $34,464 |
2019
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 25 | $926 |
2018
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 54 | $9,819 |
Drugs they prescribed that Part D paid
$54,255
Pharmacies billed $54,255 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 201) in 2024. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 0%.
159 generic and 42 brand-name prescriptions · $54,255 in drug cost · 46 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Anoro Ellipta | 14 | $10,097 | $721 |
| Sirolimus | 26 | $9,541 | $367 |
| Everolimus | 11 | $6,910 | $628 |
| Ethambutol | 27 | $3,243 | $120 |
| Azithromycin | 32 | $1,428 | $45 |
Year by year
| 2024 | 201 | 47 | 0% (0) | 21% | $54,255 |
| 2023 | 288 | 49 | 0% (0) | None | $93,366 |
| 2022 | 372 | 47 | None | None | $107,512 |
| 2021 | 283 | 44 | 0% (0) | 37% | $89,088 |
| 2020 | 419 | 52 | None | 36% | $111,731 |
| 2019 | 560 | 71 | None | 34% | $197,150 |
| 2018 | 536 | 69 | 0% (0) | 44% | $176,153 |
| 2017 | 608 | 71 | 0% (0) | None | $139,305 |
| 2016 | 536 | 56 | 0% (0) | None | $102,488 |
| 2015 | 452 | 53 | 0% (0) | 48% | $136,237 |
| 2014 | 519 | 67 | None | 50% | $111,370 |
| 2013 | 402 | 66 | None | 54% | $118,226 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Sirolimus | 28 | $11,238 | $401 |
| Anoro Ellipta | 11 | $10,613 | $965 |
| Ethambutol | 59 | $4,820 | $82 |
| Azithromycin | 62 | $3,183 | $51 |
| Rifampin | 14 | $1,202 | $86 |
| Albuterol Sulfate Hfa | 17 | $533 | $31 |
2022: 8 drugs
| Anoro Ellipta | 25 | $18,362 | $734 |
| Imipenem-Cilastatin | 43 | $12,529 | $291 |
| Sirolimus | 32 | $9,777 | $306 |
| Ethambutol | 56 | $5,584 | $100 |
| Azithromycin | 67 | $4,402 | $66 |
| Rifampin | 29 | $4,119 | $142 |
| Montelukast | 11 | $336 | $31 |
| Prednisone | 12 | $109 | $9 |
2021: 8 drugs
| Anoro Ellipta | 33 | $26,055 | $790 |
| Spiriva | 17 | $12,931 | $761 |
| Sirolimus | 24 | $10,678 | $445 |
| Flovent Hfa | 13 | $9,500 | $731 |
| Azithromycin | 44 | $2,657 | $60 |
| Ethambutol | 24 | $2,254 | $94 |
| Montelukast | 13 | $263 | $20 |
| Prednisone | 16 | $247 | $15 |
2020: 11 drugs
| Anoro Ellipta | 34 | $20,604 | $606 |
| Spiriva | 19 | $14,763 | $777 |
| Flovent Hfa | 15 | $11,423 | $762 |
| Sirolimus | 22 | $9,978 | $454 |
| Itraconazole | 15 | $6,735 | $449 |
| Ethambutol | 55 | $3,951 | $72 |
| Azithromycin | 46 | $3,507 | $76 |
| Rifampin | 21 | $2,030 | $97 |
| Albuterol Sulfate Hfa | 18 | $897 | $50 |
| Montelukast | 26 | $491 | $19 |
| Prednisone | 22 | $193 | $9 |
2019: 13 drugs
| Spiriva | 32 | $19,865 | $621 |
| Anoro Ellipta | 27 | $17,702 | $656 |
| Sirolimus | 18 | $14,140 | $786 |
| Flovent Hfa | 16 | $10,473 | $655 |
| Itraconazole | 14 | $7,998 | $571 |
| Symbicort | 11 | $7,037 | $640 |
| Ethambutol | 92 | $4,947 | $54 |
| Azithromycin | 81 | $3,059 | $38 |
| Rifampin | 36 | $2,916 | $81 |
| Proair Hfa | 13 | $1,169 | $90 |
| Montelukast | 27 | $531 | $20 |
| Prednisone | 34 | $202 | $6 |
| Levofloxacin | 11 | $117 | $11 |
2018: 14 drugs
| Sirolimus | 23 | $32,899 | $1,430 |
| Spiriva | 51 | $26,059 | $511 |
| Advair Diskus | 35 | $16,462 | $470 |
| Anoro Ellipta | 25 | $16,421 | $657 |
| Flovent Hfa | 15 | $9,013 | $601 |
| Symbicort | 16 | $7,551 | $472 |
| Ethambutol | 73 | $4,113 | $56 |
| Amikacin Sulfate | 23 | $3,444 | $150 |
| Azithromycin | 67 | $2,555 | $38 |
| Rifampin | 36 | $2,537 | $70 |
| Proair Hfa | 11 | $861 | $78 |
| Montelukast | 22 | $406 | $18 |
| Fluticasone Propionate | 14 | $266 | $19 |
| Prednisone | 13 | $82 | $6 |
2017: 14 drugs
| Sirolimus | 42 | $40,892 | $974 |
| Spiriva | 47 | $20,086 | $427 |
| Advair Diskus | 21 | $8,407 | $400 |
| Flovent Hfa | 13 | $7,900 | $608 |
| Symbicort | 14 | $6,600 | $471 |
| Ethambutol | 78 | $4,936 | $63 |
| Rifampin | 60 | $4,551 | $76 |
| Xarelto | 11 | $4,236 | $385 |
| Azithromycin | 85 | $3,950 | $46 |
| Levalbuterol Tartrate Hfa | 17 | $1,000 | $59 |
| Methotrexate | 12 | $396 | $33 |
| Fluticasone Propionate | 20 | $376 | $19 |
| Montelukast | 15 | $313 | $21 |
| Prednisone | 20 | $179 | $9 |
2016: 14 drugs
| Sirolimus | 28 | $19,824 | $708 |
| Spiriva | 30 | $14,494 | $483 |
| Advair Diskus | 35 | $13,584 | $388 |
| Flovent Hfa | 11 | $5,169 | $470 |
| Rifampin | 54 | $4,297 | $80 |
| Xarelto | 11 | $3,872 | $352 |
| Qvar | 14 | $3,734 | $267 |
| Ethambutol | 77 | $3,589 | $47 |
| Azithromycin | 82 | $3,277 | $40 |
| Ventolin Hfa | 12 | $721 | $60 |
| Methotrexate | 12 | $395 | $33 |
| Fluticasone Propionate | 13 | $204 | $16 |
| Pantoprazole | 14 | $167 | $12 |
| Prednisone | 11 | $99 | $9 |
2015: 11 drugs
| Spiriva | 61 | $24,221 | $397 |
| Flovent Hfa | 21 | $9,246 | $440 |
| Symbicort | 19 | $7,015 | $369 |
| Qvar | 17 | $5,631 | $331 |
| Advair Diskus | 14 | $3,497 | $250 |
| Azithromycin | 56 | $3,257 | $58 |
| Ethambutol | 26 | $1,307 | $50 |
| Rifampin | 15 | $1,025 | $68 |
| Fluticasone Propionate | 25 | $311 | $12 |
| Prednisone | 12 | $117 | $10 |
| Sulfamethoxazole-Trimethoprim | 12 | $90 | $8 |
2014: 13 drugs
| Spiriva | 81 | $29,660 | $366 |
| Rapamune | 19 | $18,957 | $998 |
| Flovent Hfa | 21 | $7,737 | $368 |
| Qvar | 24 | $7,627 | $318 |
| Advair Diskus | 22 | $5,994 | $272 |
| Ethambutol | 25 | $2,240 | $90 |
| Azithromycin | 34 | $1,849 | $54 |
| Rifampin | 13 | $1,815 | $140 |
| Proair Hfa | 26 | $1,259 | $48 |
| Montelukast | 12 | $463 | $39 |
| Prednisone | 22 | $273 | $12 |
| Theophylline Anhydrous | 11 | $150 | $14 |
| Fluticasone Propionate | 16 | $149 | $9 |
2013: 13 drugs
| Spiriva | 61 | $21,903 | $359 |
| Rapamune | 16 | $18,686 | $1,168 |
| Flovent Hfa | 19 | $10,024 | $528 |
| Advair Diskus | 15 | $5,424 | $362 |
| Qvar | 15 | $5,089 | $339 |
| Proair Hfa | 40 | $2,274 | $57 |
| Azithromycin | 25 | $1,871 | $75 |
| Ethambutol | 14 | $1,423 | $102 |
| Rifampin | 12 | $826 | $69 |
| Fluticasone Propionate | 19 | $496 | $26 |
| Amox Tr-Potassium Clavulanate | 11 | $421 | $38 |
| Prednisone | 12 | $90 | $7 |
| Levothyroxine | 12 | $79 | $7 |
Money from drug and device companies
$11,233 in 2024
| 2024 | 2 | 15 | $8,980 | $11,233 |
| 2023 | 1 | 1 | None | $73 |
| 2021 | 1 | 3 | $1,665 | $1,799 |
| 2019 | 1 | 1 | $400 | $400 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Insmed | Arikayce | $11,103 | 14 payments
|
| Mannkind | Afrezza | $130 | 1 payment
|
See all 15 published payments
| Insmed | Education · 2024-12-05 | Arikayce | $1 |
| Insmed | Meals · 2024-10-23 | None | $25 |
| Insmed | Travel · 2024-10-23 | None | $51 |
| Insmed | Consulting · 2024-10-11 | None | $8,980 |
| Insmed | Travel · 2024-09-22 | None | $416 |
| Insmed | Travel · 2024-09-22 | None | $638 |
| Insmed | Meals · 2024-09-21 | None | $22 |
| Insmed | Meals · 2024-09-21 | None | $24 |
| Insmed | Meals · 2024-09-21 | None | $50 |
| Insmed | Meals · 2024-09-21 | None | $40 |
| Insmed | Meals · 2024-09-20 | None | $50 |
| Insmed | Meals · 2024-09-20 | None | $150 |
| Insmed | Meals · 2024-09-20 | None | $24 |
| Insmed | Travel · 2024-08-15 | None | $632 |
| Mannkind | Meals · 2024-05-20 | Afrezza | $130 |
See earlier years (2023, 2021, 2019)
2023: $73
| Insmed | Arikayce | $73 | 1 payment
|
2021: $1,799
| Paratek Pharmaceuticals | Nuzyra | $1,799 | 3 payments
|
2019: $400
| Insmed | Arikayce | $400 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Insmed, Inc. · A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study To Evaluate the Efficacy and Safety of An Amikacin Liposome Inhalation Suspension (Alis)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact · 2022 | Their institution | $210,645 |
| Insmed, Inc. · A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study To Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (Ntm) Lung Infection Caused By Mycobacterium Avium Complex (Arise) · 2022 | Their institution | $180,562 |
| Insmed, Inc. · A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study To Evaluate the Efficacy and Safety of An Amikacin Liposome Inhalation Suspension (Alis)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact · 2023 | Their institution | $48,985 |
| Paratek Pharmaceuticals, Inc. · A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study To Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With Ntm Pulmonary Disease Caused By Mycobacterium Abscessus Complex · 2023 | Their institution | $37,981 |
| Mannkind Corporation · Icon-1 Phase 3 Study of the Efficacy and Safety of Treatment With Mnkd-101, Clofazamine Inhalation Suspension · 2025 | Their institution | $24,879 |
| Paratek Pharmaceuticals, Inc. · A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study To Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With Ntm Pulmonary Disease Caused By Mycobacterium Abscessus Complex · 2022 | Their institution | $21,628 |
| Insmed, Inc. · A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (Lai) in Adult Patients With Nontuberculous Mycobacterial (Ntm) Lung Infection Caused By Mycobacterium Avium Complex (Mac) That Are Refractory To Treatment · 2019 | Their institution | $18,598 |
| Insmed, Inc. · A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study To Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (Ntm) Lung Infection Caused By Mycobacterium Avium Complex (Arise) · 2023 | Their institution | $15,431 |
| Paratek Pharmaceuticals, Inc. · A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study To Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With Ntm Pulmonary Disease Caused By Mycobacterium Abscessus Complex · 2025 | Their institution | $12,081 |
| Insmed, Inc. · An Open-Label Safety Extension Study To A Multicenter Study of Liposomal Amikacin for Inhalation (Lai) in Adult Patients With Nontuberculous Mycobacterial (Ntm) Lung Infections Caused By Mycobacterium Avium Complex (Mac) That Are Refractory To Treatment · 2019 | Their institution | $11,920 |
| Insmed, Inc. · A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study To Evaluate the Efficacy and Safety of An Amikacin Liposome Inhalation Suspension (Alis)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact · 2024 | Their institution | $10,435 |
| Insmed, Inc. · Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study To Assess the Efficacy, Safety & Tolerability, and Pk of Ins1007 Administered Once Daily for 24 Weeks in Subjects With Non-Cf Bronchiectasis - the Willow Study · 2020 | Their institution | $9,394 |
| Insmed, Inc. · A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study To Evaluate the Efficacy and Safety of An Amikacin Liposome Inhalation Suspension (Alis)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact · 2025 | Their institution | $6,203 |
| Insmed, Inc. · A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study To Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (Ntm) Lung Infection Caused By Mycobacterium Avium Complex (Arise) · 2024 | Their institution | $5,629 |
| Paratek Pharmaceuticals, Inc. · A Ph. 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study To Evaluate the Efficacy, Safety, & Tolerability of Oral Omadacycline in Adults With Ntm Pulmonary Disease Caused By Mycobacterium Abscessus Complex · 2024 | Their institution | $5,473 |
| Mannkind Corporation · Mnkd-101 · 2024 | Their institution | $1,392 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1255472858
- Licence
- CA G57078California G57078: Current · expires 2028-01-31
- Trained
- University of Washington School of Medicine, 1981
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 300 Pasteur Dr, H3149, Stanford, CA, 94305
- NPI first listed
- 2007-02-08
- NPI last updated
- 2011-10-04
This is when the NPI record was last certified, not a medical board exam.